Construction and external validation of radiomics models to detect primary prostate cancer with machine learning: a multicenter study based on <sup>68</sup>Ga-PSMA PET/CT.
Authors
Affiliations (8)
Affiliations (8)
- Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
- Department of Urology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China.
- Department of Urology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Research Institute of Shandong University: Magnetic Field-free Medicine & Functional Imaging, Jinan, China.
- Department of Nuclear Medicine, Affiliated Hospital of Qingdao University, Qingdao, China.
- Department of PET Center, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
- Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
- Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China.
Abstract
Recent studies have shown that <sup>68</sup>Ga-prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA) positron emission tomography/computed tomography (PET/CT) can open a non-invasive diagnostic pathway in prostate cancer (PCa). However, the relatively small number of enrolled patients in these studies limits statistical validation and causes bias to some extent. In addition, the performance of <sup>68</sup>Ga-PSMA PET/CT radiomics analysis in detecting PCa has not been widely evaluated. Hence, the present multicenter study endeavored to develop and validate radiomics models based on <sup>68</sup>Ga-PSMA PET/CT for the detection of primary PCa in a relatively larger cohort. This study enrolled consecutive patients with suspected PCa who underwent systematic biopsy (SB) and PSMA PET/CT-targeted biopsy (TB) after <sup>68</sup>Ga-PSMA PET/CT in three medical centers. The whole prostate gland was adopted as the volume of interest (VOI). Eight machine learning (ML) algorithms were utilized to develop models with selected radiomics features separately, after which the best-performing radiomics model was integrated with maximum standardized uptake value (SUVmax) to create the combined model. The receiver operating characteristic (ROC) curves and area under the curve (AUC) value, accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for each model. Overall, 609 patients were recruited, including 195 patients with benign prostate diseases (BPD), 30 patients with clinically insignificant prostate cancer (ciPCa, Gleason score [GS] = 3 + 3), and 384 patients with clinically significant prostate cancer (csPCa, GS ≥ 3 + 4). For csPCa prediction, the radiomics model developed by the eXtreme Gradient Boosting (XGBoost) algorithm demonstrated the best performance. After integrating with SUVmax, the combined model achieved the highest AUC of 0.921 in internal validation cohort. External validation cohort 1 and 2 also showed promising results with AUC of 0.906 and 0.898, respectively. For PCa prediction, the XGBoost algorithm combined with SUVmax also peformed well in three validation cohorts with the AUC ranging from 0.860 to 0.918. This is the largest multicenter study to date, providing a noninvasive and quantitative method based on <sup>68</sup>Ga-PSMA PET/CT radiomics analysis modeled with ML for predicting PCa. This method has the potential to gauge the risk of PCa before biopsy.